Lupus Research Alliance News
Virtual Events Were Real-ly Successful!

While the pandemic made it impossible for the LRA to hold in person fundraising events, we still achieved great success thanks to the determination of our supporters to fund crucial lupus research. Likewise, our “virtual gala” – bolstered by superstars like Lady Gaga and Selena Gomez – raised an astounding $3.3 million and was attended […] READ MORE

LRA Shares Tremendous Loss of Lupus Research Hero Dr. Marc Chevrier

February 10, 2021 The worldwide lupus community lost a brilliant researcher and a passionate champion with the recent passing of rheumatologist Marc Chevrier, MD, PhD, FACR.  A larger-than-life personality with a huge heart to match, Dr. Chevrier was a devoted friend to hundreds of people with lupus and those who care for them.  Perhaps most […] READ MORE

Lupus Nephritis: A Major Focus at the Lupus Research Alliance

January 28, 2021 Developing safe and effective treatments for lupus nephritis has been an urgent and long-standing goal in the lupus community. As the leading private funding agency for lupus research, the LRA and its legacy organizations have dedicated significant focus and resources towards addressing this continued challenge, awarding over 40 grants to address this […] READ MORE

New CDC Study Estimates 204,295 Americans Have Lupus

January 29, 2021 According to a new analysis funded by the Centers for Disease Control and Prevention, about 204,295 Americans have systemic lupus erythematosus (SLE), based on strict criteria for diagnosis by the American College of Rheumatology. These data, however, do not include cutaneous lupus. Based on an analysis of five studies, the national estimate […] READ MORE

Lupus Research Alliance Hails Approval of Aurinia’s Lupkynis(TM) (voclosoporin)

First Oral Treatment for Lupus Nephritis; Second Lupus Treatment to Receive FDA Approval in Past Month NEW YORK, NY. January 22. The Lupus Research Alliance (LRA) is excited to share that the U.S. Food and Drug Administration (FDA) approved the use of Aurinia Pharmaceuticals’ LupkynisTM (voclosporin) as the first oral treatment developed specifically for adults […] READ MORE

Update from LRA’s President on COVID-19 Vaccines in Lupus

January 14, 2020 Dear Friends, Happy New Year! On behalf of all of us at the Lupus Research Alliance (LRA), thank you so much for your kindness and generosity in 2020 and prior years. 2021 starts off with some exciting milestones for the lupus community including a new treatment for lupus nephritis. But  Recently, our […] READ MORE

Vaccines and Lupus: What to Know Amid COVID-19

January 14, 2020 LRA’s President and CEO Kenneth Farber taped this video series – Vaccines and Lupus: What to Know Amid COVID-19 – to explain what vaccines do, how the new COVID-19 vaccine technologies work, and what the LRA is doing to address questions on the safety of these new vaccines for people with lupus. […] READ MORE

Lupus Advocacy Delivers Again!

December 28, 2020 After much back and forth, last week the U.S. Congress passed the year-end spending deal, called the Omnibus, and President Trump signed it into law Sunday night.  It’s because of your efforts during the LRA’s Virtual Hill Day in March that the need to fund research for lupus and other medical conditions […] READ MORE

Existing Cancer Drug May Lower Inflammation in Autoimmune Diseases Like Lupus

December 14, 2020 In a recent study published in the Journal of Immunology, LRA-funded researcher Dr. John Zhang at Medical University of South Carolina found that a protein called Fli-1 causes immune cells to produce a molecule that causes inflammation. When Fli-1 was hindered by the chemotherapeutic drug camptothecin, immune cells produced fewer inflammatory molecules. […] READ MORE

Learn and connect with our community!